Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29912669 | 1.00 | TPMT (0.44) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL347092 | 0.85 | TPMT (0.59) | TPMTHCAR1HPGDPARP1HCAR2 | |
| SCHEMBL4360630 | 0.85 | TPMT (0.52) | TPMTHCAR1CES2CES1GPR35 | |
| SCHEMBL93282 | 0.83 | TPMT (0.62) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL3358922 | 0.83 | TPMT (0.55) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL12372142 | 0.82 | TPMT (0.44) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL2172133 | 0.82 | TPMT (0.70) | TPMTKDRHCAR1CNR2HCAR2 | |
| SCHEMBL2172128 | 0.82 | TPMT (0.44) | TPMTKDRHCAR1CES2CES1 | |
| Hydrochloric Acid SCHEMBL28632192 | 0.80 | TPMT (0.59) | TPMTKDRHCAR1PARP1HCAR2 | |
| SCHEMBL22383502 | 0.80 | PARP1 (0.50) | TPMTKDRHCAR1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023171980-A1 | NOVEL TAFAMIDIS SYNTHESIS METHOD | 고려대학교 산학협력단 | 2023-09-14 | — | — | WO | disclosed |
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2463269-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160039750-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2016-02-11 | — | — | US | disclosed |
| US-9255273-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-02-09 | — | — | US | disclosed |
| EP-2460786-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9169210-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150240244-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2015-08-27 | — | — | US | disclosed |
| US-9102648-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2015-08-11 | — | — | US | disclosed |
| EP-0461809-A1 | Dibenzoylalkylcyanohydrazines | ROHM AND HAAS COMPANY (US) | 1991-12-18 | — | — | EP | disclosed |
| US-4895984-A | Using Friedel-crafts catalyst | BASF AKTIENGESELLSCHAFT (DE) | 1990-01-23 | — | — | US | disclosed |
| EP-0248423-B1 | PROCESS OR THE ACYLATION OF AROMATIC COMPOUNDS | BASF Aktiengesellschaft (DE) | 1989-08-30 | — | — | EP | disclosed |
| EP-0248423-A1 | Process or the acylation of aromatic compounds | BASF Aktiengesellschaft (DE) | 1987-12-09 | — | — | EP | disclosed |
| US-4585866-A | Treatment of migraine with substituted tropyl benzoate derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-04-29 | — | — | US | disclosed |
| US-4563465-A | ANTISEROTONINE AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-01-07 | — | — | US | disclosed |
| EP-0012850-B1 | PROCESS FOR THE PREPARATION OF KETONES BY REACTING CARBOXYLIC-ACID HALIDES WITH ALKYL ALUMINIUM COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-11-25 | — | — | EP | disclosed |
| US-4266066-A | FROM CARBOXYLIC ACYL HALIDE AND ALUMINUM ALKYL COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| US-4180525-A | OLIGOMERIZING OLEFINS | PHILLIPS PETROLEUM COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4123447-A | REACTING (1,5-CYCLOOCTADIENE)BIS(TRIETHYLPHOSPHINE)-NICKEL(O) WITH AN ACYL HALIDE, OLIGOMERIZATION CATALYSTS | PHILLIPS PETROLEUM COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039750-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, NR5A1, NR5A2 | TPMT 4189/4885KDR 868/4885HCAR1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.